| Year |
Citation |
Score |
| 2021 |
Lehmann BD, Colaprico A, Silva TC, Chen J, An H, Ban Y, Huang H, Wang L, James JL, Balko JM, Gonzalez-Ericsson PI, Sanders ME, Zhang B, Pietenpol JA, Chen XS. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nature Communications. 12: 6276. PMID 34725325 DOI: 10.1038/s41467-021-26502-6 |
0.347 |
|
| 2020 |
Korolkova OY, Widatalla SE, Whalen DS, Nangami GN, Abimbola A, Williams SD, Beasley HK, Reisenbichler E, Washington MK, Ochieng J, Mayer IA, Lehmann BD, Sakwe AM. Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. Plos One. 15: e0231711. PMID 32298357 DOI: 10.1371/Journal.Pone.0231711 |
0.403 |
|
| 2020 |
Schafer JM, Lehmann BD, Gonzalez-Ericsson PI, Marshall CB, Beeler JS, Redman LN, Jin H, Sanchez V, Stubbs MC, Scherle P, Johnson KN, Sheng Q, Roland JT, Bauer JA, Shyr Y, et al. Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. Science Translational Medicine. 12. PMID 32161105 DOI: 10.1126/Scitranslmed.Aaw8275 |
0.486 |
|
| 2020 |
Lander EM, Lehmann BD, Shah PD, Dees EC, Ballinger TJ, Pohlmann PR, Santa-Maria CA, Shyr Y, Mayer IA, Park BH, Pietenpol JA, Abramson VG. A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC). Journal of Clinical Oncology. 38: TPS1112-TPS1112. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps1112 |
0.377 |
|
| 2019 |
Lehmann BD, Abramson VG, Sanders M, Mayer EL, Haddad T, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, et al. TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31822498 DOI: 10.1158/1078-0432.Ccr-19-2170 |
0.398 |
|
| 2019 |
Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sanchez V, Shyr Y, Sanders ME, Pietenpol JA. Identification of targetable recurrent MAP3K8 rearrangements in melanomas lacking known driver mutations. Molecular Cancer Research : McR. PMID 31186280 DOI: 10.1158/1541-7786.Mcr-19-0257 |
0.425 |
|
| 2019 |
Whalen DS, Widatalla SE, Korolkova OY, Nangami GS, Beasley HK, Williams SD, Virgous C, Lehmann BD, Ochieng J, Sakwe AM. Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility. Oncotarget. 10: 133-151. PMID 30719209 DOI: 10.18632/Oncotarget.26512 |
0.425 |
|
| 2019 |
Gonzalez-Ericsson P, Lehmann B, Mobley B, Chen Y, Pietenpol J, Sanders M. Abstract P2-06-09: Identification of oncogenic gene fusions in triple-negative breast cancer metastatic to the brain Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P2-06-09 |
0.452 |
|
| 2019 |
Lehmann BD, Colaprico A, Chen J, Wang L, Pietenpol J, Chen X. Abstract LB-301: Integrative genomic analysis identifies distinct mutational, epigenetic and immunological patterns among triple-negative breast cancer subtypes Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-301 |
0.486 |
|
| 2018 |
Rida P, Ogden A, Ellis IO, Varga Z, Wolff AC, Traina TA, Hatzis C, Palmer JR, Ambrosone CB, Lehmann BD, Nanda R, Montgomery Rice V, Brawley OW, Torres MA, Rakha E, et al. First international TNBC conference meeting report. Breast Cancer Research and Treatment. PMID 29417299 DOI: 10.1007/S10549-018-4692-3 |
0.381 |
|
| 2018 |
Guo Y, Yu H, Wang J, Sheng Q, Zhao S, Zhao YY, Lehmann BD. The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer. Genes. 9. PMID 29320459 DOI: 10.3390/Genes9010029 |
0.438 |
|
| 2018 |
Schafer J, Lehmann B, Redman L, Liu P, Stubbs M, Ruggeri B, Scherle P, Pietenpol J. Abstract P2-09-24: Combination treatment with bromodomain and extra-terminal motif inhibitors in triple-negative breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-09-24 |
0.518 |
|
| 2017 |
Zhang P, Lehmann BD, Samuels DC, Zhao S, Zhao YY, Shyr Y, Guo Y. Estimating relative mitochondrial DNA copy number using high throughput sequencing data. Genomics. PMID 28734953 DOI: 10.1016/J.Ygeno.2017.07.002 |
0.358 |
|
| 2017 |
Jovanović B, Sheng Q, Seitz RS, Lawrence KD, Morris SW, Thomas LR, Hout DR, Schweitzer BL, Guo Y, Pietenpol JA, Lehmann BD. Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. Bmc Cancer. 17: 241. PMID 28376728 DOI: 10.1186/S12885-017-3237-1 |
0.431 |
|
| 2017 |
Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders M, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KN, Sanchez V, Rosenbluth JM, Dillon PM, Forrero-Torres A, ... ... Lehmann BD, et al. A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28270498 DOI: 10.1158/1078-0432.Ccr-16-3055 |
0.393 |
|
| 2017 |
Liu PCC, Lehmann BD, Ruggeri B, DiMatteo D, Schafer JM, Lu J, Lee SH, Lin L, Burn TC, Diamond M, Volgina A, Wu L, Hollis G, Huber R, Pietenpol JA, et al. Abstract 531: Activity of the selective FGFR 1, 2 and 3 inhibitor INCB054828 in genetically-defined models of triple-negative breast cancer Cancer Research. 77: 531-531. DOI: 10.1158/1538-7445.Am2017-531 |
0.502 |
|
| 2017 |
Schafer J, Lehmann B, Liu P, Stubbs M, Scherle P, Pietenpol J. Abstract 1518: Mechanisms of bromodomain and extra-terminal motif inhibitor (BETi) sensitivity in triple-negative breast cancer (TNBC) Cancer Research. 77: 1518-1518. DOI: 10.1158/1538-7445.Am2017-1518 |
0.515 |
|
| 2016 |
Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. Plos One. 11: e0157368. PMID 27310713 DOI: 10.1371/Journal.Pone.0157368 |
0.442 |
|
| 2016 |
Shaver TM, Lehmann BD, Beeler JS, Li CI, Li Z, Jin H, Stricker TP, Shyr Y, Pietenpol JA. Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. Cancer Research. PMID 27231203 DOI: 10.1158/0008-5472.Can-16-0058 |
0.475 |
|
| 2016 |
Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. Bmc Cancer. 16: 143. PMID 26908167 DOI: 10.1186/S12885-016-2198-0 |
0.387 |
|
| 2015 |
Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast (Edinburgh, Scotland). 24: S36-40. PMID 26253813 DOI: 10.1016/J.Breast.2015.07.009 |
0.427 |
|
| 2015 |
Lehmann BD, Pietenpol JA, Tan AR. Triple-negative breast cancer: molecular subtypes and new targets for therapy. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. e31-9. PMID 25993190 DOI: 10.14694/EdBook_AM.2015.35.e31 |
0.308 |
|
| 2015 |
Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget. PMID 25972361 DOI: 10.18632/Oncotarget.3860 |
0.47 |
|
| 2015 |
Mohni KN, Thompson PS, Luzwick JW, Glick GG, Pendleton CS, Lehmann BD, Pietenpol JA, Cortez D. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. Plos One. 10: e0125482. PMID 25965342 DOI: 10.1371/Journal.Pone.0125482 |
0.407 |
|
| 2015 |
Lehmann BD, Ding Y, Viox DJ, Jiang M, Zheng Y, Liao W, Chen X, Xiang W, Yi Y. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value. Bmc Cancer. 15: 179. PMID 25886164 DOI: 10.1186/S12885-015-1102-7 |
0.466 |
|
| 2015 |
Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 121: 8-16. PMID 25043972 DOI: 10.1002/Cncr.28914 |
0.408 |
|
| 2015 |
Wilson AJ, Lehmann BD, Liu Q, Uddin J, Elleman A, Crews B, Saskowski J, Pietenpol J, Marnett LJ, Khabele D. Abstract POSTER-BIOL-1350: Dissecting cellular and molecular consequences of disrupting cyclooxygenase-1 activity in ovarian cancer Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Biol-1350 |
0.51 |
|
| 2015 |
Seitz RS, Hout DR, Morris SW, Smith RB, Lehmann BD, Chen X, Pietenpol JA, Ring BZ. Abstract P6-08-04: Creation of a robust algorithm utilizing minimal gene sets normalized against a reference gene set to identify triple-negative breast cancer (TNBC) subtypes Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-08-04 |
0.417 |
|
| 2015 |
Jovanovic B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL. Abstract P6-03-04: TGF-β receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-03-04 |
0.449 |
|
| 2015 |
Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gomez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. Abstract P3-04-03: PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-04-03 |
0.481 |
|
| 2015 |
Wilson AJ, Lehmann BD, Saskowski J, Uddin J, Daniel C, Crews BC, Liu Q, Zhao S, Son D, Pietenpol JA, Marnett LJ, Khabele D. Abstract 2068: Cyclooxygenase-1 gene expression contributes to multiple oncogenic pathways in high grade serous ovarian cancer Cancer Research. 75: 2068-2068. DOI: 10.1158/1538-7445.Am2015-2068 |
0.513 |
|
| 2014 |
Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Research : Bcr. 16: 406. PMID 25103565 DOI: 10.1186/S13058-014-0406-X |
0.449 |
|
| 2014 |
Jovanovi? B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer. Breast Cancer Research : Bcr. 16: R69. PMID 24985072 DOI: 10.1186/Bcr3684 |
0.419 |
|
| 2014 |
Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Cancer Research. 74: 3180-94. PMID 24662921 DOI: 10.1158/0008-5472.Can-13-3415 |
0.503 |
|
| 2014 |
Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 782-90. PMID 24536073 DOI: 10.1158/1078-0432.Ccr-13-0583 |
0.437 |
|
| 2014 |
Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, ... ... Lehmann BD, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discovery. 4: 232-45. PMID 24356096 DOI: 10.1158/2159-8290.Cd-13-0286 |
0.438 |
|
| 2014 |
Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. The Journal of Pathology. 232: 142-50. PMID 24114677 DOI: 10.1002/Path.4280 |
0.422 |
|
| 2014 |
Abramson VG, Lehmann B, Mayer IA, Arteaga CL, Pietenpol JA. TBCRC028: A phase Ib/II trial of GDC-0941 (a PI3K inhibitor) in combination with cisplatin in metastatic androgen receptor-negative triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps1148 |
0.416 |
|
| 2014 |
Wilson AJ, Lehmann BD, Ussin J, Elleman A, Crews B, Saskowski J, Pietenpol J, Marnett LJ, Khabele D. Abstract 4928: Cyclooxygenase-1 as a target for molecular imaging of high grade serous ovarian cancer Cancer Research. 74: 4928-4928. DOI: 10.1158/1538-7445.Am2014-4928 |
0.474 |
|
| 2013 |
Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6696-702. PMID 24345920 DOI: 10.1158/1078-0432.Ccr-13-1746 |
0.315 |
|
| 2013 |
Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5533-40. PMID 23948975 DOI: 10.1158/1078-0432.Ccr-13-0799 |
0.414 |
|
| 2013 |
Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann BD, Strand DW, Jovanovic B, DeGraff DJ, Zheng Y, Yousif DA, Simmons CQ, Case TC, Yi J, Cates JM, Virostko J, et al. SPARCL1 suppresses metastasis in prostate cancer. Molecular Oncology. 7: 1019-30. PMID 23916135 DOI: 10.1016/J.Molonc.2013.07.008 |
0.462 |
|
| 2013 |
Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2723-33. PMID 23549873 DOI: 10.1158/1078-0432.Ccr-12-2986 |
0.427 |
|
| 2013 |
Qiu Q, Lu P, Xiang Y, Shyr Y, Chen X, Lehmann BD, Viox DJ, George AL, Yi Y. A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer. Plos One. 8: e54979. PMID 23383020 DOI: 10.1371/Journal.Pone.0054979 |
0.397 |
|
| 2013 |
Landis MD, Lehmann BD, Pietenpol JA, Chang JC. Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Research : Bcr. 15: 201. PMID 23339383 DOI: 10.1186/Bcr3355 |
0.499 |
|
| 2013 |
Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer. Journal of Clinical Oncology. 31: 1005-1005. DOI: 10.1200/Jco.2013.31.15_Suppl.1005 |
0.393 |
|
| 2013 |
Jovanovic B, Chen SX, Lehmann BD, Johnson KN, Sanchez V, Kuba MG, Sanders ME, Mayer IA, Moses HL, Pietenpol JA. Abstract 4698: Gene expression profiles of triple negative breast cancer epithelial and stromal cells are predictive of treatment response. Cancer Research. 73: 4698-4698. DOI: 10.1158/1538-7445.Am2013-4698 |
0.465 |
|
| 2013 |
Mayer I, Jovanovic B, Abramson V, Mayer E, Sanders M, Bardia A, Dillon P, Kuba M, Carpenter J, Chang J, Lehmann B, Meszoely I, Grau A, Shyr Y, Arteaga C, et al. Abstract PD1-6: A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC) Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Pd1-6 |
0.419 |
|
| 2012 |
Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle (Georgetown, Tex.). 11: 4579-88. PMID 23187804 DOI: 10.4161/Cc.22852 |
0.733 |
|
| 2012 |
Lehmann BD, Pietenpol JA. Targeting mutant p53 in human tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3648-50. PMID 22965952 DOI: 10.1200/Jco.2012.44.0412 |
0.441 |
|
| 2012 |
Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA. TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Informatics. 11: 147-56. PMID 22872785 DOI: 10.4137/Cin.S9983 |
0.47 |
|
| 2012 |
Lehmann B, Bauer J, Schafer J, Tang L, Pendleton C, Sanders M, Pietenpol J. Abstract P6-05-03: Targeted inhibition of recurrent PIK3CA mutations synergizes with bicalutamide in AR-expressing triple negative breast cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P6-05-03 |
0.547 |
|
| 2011 |
Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget. 2: 610-26. PMID 21881167 DOI: 10.18632/Oncotarget.315 |
0.511 |
|
| 2011 |
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of Clinical Investigation. 121: 2750-67. PMID 21633166 DOI: 10.1172/Jci45014 |
0.51 |
|
| 2011 |
Bauer JA, Lehmann BD, Glick G, Cortez D, Lee E, Pietenpol JA. Abstract 951: Loss-of-function screening identifies therapeutic targets for triple negative breast cancer (TNBC) Cancer Research. 71: 951-951. DOI: 10.1158/1538-7445.Am2011-951 |
0.514 |
|
| 2011 |
Lehmann BD, Bauer JA, Sanders ME, Chakravarthy BA, Pietenpol JA. Abstract 4411: γH2AX as a marker of genomic instability predicts cisplatin sensitivity in triple negative breast cancer cells Cancer Research. 71: 4411-4411. DOI: 10.1158/1538-7445.Am2011-4411 |
0.483 |
|
| 2011 |
Greenbaum M, Wiltshire T, Glick G, Bauer J, Lehmann B, Pietenpol J, Cortez D. Synthetic Lethal Relationships in the DNA Damage Response of Triple Negative Breast Cancer International Journal of Radiation Oncology*Biology*Physics. 81: S26. DOI: 10.1016/J.Ijrobp.2011.06.054 |
0.4 |
|
| 2010 |
Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Research : Bcr. 12: R41. PMID 20576088 DOI: 10.1186/Bcr2595 |
0.508 |
|
| 2010 |
Lehmann B, Bauer J, Chen X, Sanders M, Shyr Y, Pietenpol J. Abstract PD01-07: Transcriptome Analysis of Triple Negative Breast Cancers Identifies Six Distinct Biological Subgroups and Reveals Therapeutic Strategies Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-Pd01-07 |
0.503 |
|
| 2008 |
Lehmann BD, Paine MS, Brooks AM, McCubrey JA, Renegar RH, Wang R, Terrian DM. Senescence-associated exosome release from human prostate cancer cells. Cancer Research. 68: 7864-71. PMID 18829542 DOI: 10.1158/0008-5472.Can-07-6538 |
0.699 |
|
| 2008 |
Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, Martelli AM, Steelman LS, McCubrey JA. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle (Georgetown, Tex.). 7: 1745-62. PMID 18594202 DOI: 10.4161/Cc.7.12.6166 |
0.724 |
|
| 2008 |
McCubrey JA, Sokolosky ML, Lehmann BD, Taylor JR, Navolanic PM, Chappell WH, Abrams SL, Stadelman KM, Wong EW, Misaghian N, Horn S, Bäsecke J, Libra M, Stivala F, Ligresti G, et al. Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. Advances in Enzyme Regulation. 48: 113-35. PMID 18423407 DOI: 10.1016/J.Advenzreg.2008.02.006 |
0.72 |
|
| 2008 |
Lehmann BD, Brooks AM, Paine MS, Chappell WH, McCubrey JA, Terrian DM. Distinct roles for p107 and p130 in Rb-independent cellular senescence. Cell Cycle (Georgetown, Tex.). 7: 1262-8. PMID 18418057 DOI: 10.4161/Cc.7.9.5945 |
0.703 |
|
| 2008 |
Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM, Leslie NR, Martelli AM, Stivala F, Libra M, Franklin RA, et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene. 27: 4086-95. PMID 18332865 DOI: 10.1038/Onc.2008.49 |
0.709 |
|
| 2007 |
Lehmann BD, McCubrey JA, Terrian DM. Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. Cancer Biology & Therapy. 6: 1165-70. PMID 18059157 DOI: 10.4161/Cbt.6.8.4544 |
0.712 |
|
| 2007 |
McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, Wong EW, Lehmann BD, Terrian DM, Basecke J, Stivala F, Libra M, Evangelisti C, Martelli AM. Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Advances in Enzyme Regulation. 47: 64-103. PMID 17382374 DOI: 10.1016/J.Advenzreg.2006.12.013 |
0.648 |
|
| 2007 |
Lehmann BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH, Terrian DM. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle (Georgetown, Tex.). 6: 595-605. PMID 17351335 DOI: 10.4161/Cc.6.5.3901 |
0.727 |
|
| 2007 |
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica Et Biophysica Acta. 1773: 1263-84. PMID 17126425 DOI: 10.1016/J.Bbamcr.2006.10.001 |
0.737 |
|
| 2006 |
Thakore CU, Lehmann BD, McCubrey JA, Terrian DM. Intracellular Signaling in Cancer Reviews in Cell Biology and Molecular Medicine. DOI: 10.1002/3527600906.Mcb.200400106 |
0.689 |
|
| Show low-probability matches. |